Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Melle – page 60

1 901 clinical trials in Melle, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Melle at a glance
1 901
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 901 trials in Melle

Open in trial search

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Lupus nephritis+2

Not yet recruiting

Phase 2 Open‑Label Trial Assessing Safety and Efficacy of Nebaprubart in Adults with IgA‑Mediated Renal Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:JJP BIOLOGICS Sp. z o.o.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:GlaxoSmithKline Biologicals

Immune response and safety of revaccination with respiratory syncytial virus glycoprotein F recombinant vaccine adjuvanted with AS01E in older adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Cardiac failure+5

Not yet recruiting

Safety and Early Effectiveness of Intramyocardial Cardiac Atrial Stem Cells Compared with Sodium Chloride in Patients with Advanced Ischemic Heart Failure

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Melle

What the registry says about research in the country

01 Aesthetic Medicine Research

Clinical investigations focusing on masseter muscle prominence treatments are being conducted to evaluate innovative therapeutic approaches. These trials aim to assess the effectiveness of neurotoxin-based interventions for facial aesthetics.

  • Facial Muscle Studies
  • Non-surgical Aesthetic Treatments
  • Muscle Prominence Reduction

Research teams are comparing therapeutic solutions against placebo controls to establish safety profiles and efficacy measures for facial contouring procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.